# Propranolol

## Inderal 10mg

| 藥物代碼           | OIND1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Adult HTN, Angina, migraine & essential tremor, Arrhythmias, anxiety tachycardia, thyrotoxicosis, Pheochromocytoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 副作用             | Cold extremities, GI & sleep disturbances, fatigue, lassitude. Deterioration in heart failure, mood changes. Isolated cases of paresthesia. Rarely bradycardia, dizziness, postural hypotension which may be associated with syncope, heart block, alopecia, thrombocytopenia, purpura, psoriasiform skin reactions, exacerbation of psoriasis, visual disturbances, CNS symptoms including hallucinations & psychoses; hypoglycaemia in children. Rashes & dry eyes (discontinue drug). Intermittent claudication, Raynaud's phenomenon, bronchospasm, increased antinuclear antibodies.Dermatologic: Dermatitis, Pruritus, UrticariaNeurologic: Dizziness (4% to 7% )Other: Fatigue (5% to 7% )                                                                                                                                                                                                                       |
| 禁忌               | History of bronchial asthma or bronchospasm, bradycardia, cardiogenic shock, hypotension, metabolic acidosis, after prolonged fasting, severe peripheral arterial circulatory disturbances, 2nd or 3rd degree heart block, sick sinus syndrome, untreated (with an alpha adrenoceptor antagonist) phaeochromocytoma, uncontrolled heart failure, Prinzmetal's angina.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 藥物保存方式       | 室溫                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 用法用量           | Angina: PO, initially, 10-20mg tid-qid; maintenance, 160-240mg/day. Arrhythmia:  Adult: PO, 10-30mg tid-qid ac.  IV, 0.5-3mg; a second dose may be given 2 min later if necessary; additional doses may be given at intervals of no less than 4hr.  Child: PO, initially, 1.5-2mg/kg/day, titrate up to a max. 16mg/kg/day in 4 doses. Essential tremor: PO, initially, 40mg bid; maintenance, 120-320mg/day in 3 doses. Hypertension: PO. Adult: Initially, 40mg bid; maintenance, 160-480mg/day.  Child: Initially, 1mg/kg/day in 2 doses; maintenance, 1-5mg/kg/day in 2-4 doses. Migraine: PO, initially, 80mg/day in divided doses; maintenance,160-240 mg/day. Pheochromocytoma: PO, 60mg/day in divided doses for 3 days before surgery; 30 mg/day in divideddoses with an adrenergic blocker as an adjunct to prolonged treatment of intolerable pheochromocytoma. Post-MI: PO, 180-240mg/day in divided doses. |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 懷孕用藥危分級     | 除非治療上需要                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 孕期用藥建議       | Human data suggest risk in 2nd and 3rd trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 附帶說明           | 1) American Academy of Pediatrics Rating: Maternal medication usually compatible with breastfeeding. 2) World Health Organization Rating: Compatible with breastfeeding. 3) Micromedex Lactation Rating: Infant risk is minimal. 4) Clinical Management a) Propranolol is excreted in human milk and the manufacturer advises caution if propranolol is administered to a nursing woman. However, propranolol is considered compatible with breastfeeding by the American Academy of Pediatrics and the World Health Organization (WHO) [888][889]. Although propranolol appears in breast milk, the concentration is too low to be pharmacologically significant to the infant. WHO recommends monitoring the infant for bradycardia, hypoglycemia, and cyanosis                                                                                                                                                       |
| 注射劑給藥建議途徑 | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 注意事項           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

